TR201903223T4 - Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. - Google Patents
Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. Download PDFInfo
- Publication number
- TR201903223T4 TR201903223T4 TR2019/03223T TR201903223T TR201903223T4 TR 201903223 T4 TR201903223 T4 TR 201903223T4 TR 2019/03223 T TR2019/03223 T TR 2019/03223T TR 201903223 T TR201903223 T TR 201903223T TR 201903223 T4 TR201903223 T4 TR 201903223T4
- Authority
- TR
- Turkey
- Prior art keywords
- tuberculosis
- vaccine
- prevent reactivation
- reactivation
- muberculosis
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000007420 reactivation Effects 0.000 title abstract 2
- 201000008827 tuberculosis Diseases 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 206010065048 Latent tuberculosis Diseases 0.000 abstract 1
- 241001467553 Mycobacterium africanum Species 0.000 abstract 1
- 241000186366 Mycobacterium bovis Species 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000033353 latent tuberculosis infection Diseases 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900539 | 2009-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201903223T4 true TR201903223T4 (tr) | 2019-03-21 |
Family
ID=43010694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/03223T TR201903223T4 (tr) | 2009-04-24 | 2010-04-23 | Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9074001B2 (enExample) |
| EP (1) | EP2421557B1 (enExample) |
| JP (2) | JP5839361B2 (enExample) |
| KR (2) | KR20120014176A (enExample) |
| CN (2) | CN102413837B (enExample) |
| AU (1) | AU2010238943B9 (enExample) |
| BR (1) | BRPI1006452A2 (enExample) |
| CA (1) | CA2759583C (enExample) |
| DK (1) | DK2421557T3 (enExample) |
| ES (1) | ES2714383T3 (enExample) |
| HK (1) | HK1204549A1 (enExample) |
| IL (1) | IL215591A (enExample) |
| MX (2) | MX2011011186A (enExample) |
| PL (1) | PL2421557T3 (enExample) |
| TR (1) | TR201903223T4 (enExample) |
| WO (1) | WO2010121618A1 (enExample) |
| ZA (1) | ZA201108564B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2457926T3 (pl) | 2005-04-29 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
| GB0618127D0 (en) * | 2006-09-14 | 2006-10-25 | Isis Innovation | Biomarker |
| UA107330C2 (uk) * | 2008-07-25 | 2014-12-25 | Глаксосмітклайн Байолоджікалз С.А. | Туберкульозний білок rv3616c та його застосування |
| WO2010010179A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A. | The tuberculosis rv2386c protein, compositions and uses thereof |
| EP2315597B1 (en) | 2008-07-25 | 2017-08-23 | GlaxoSmithKline Biologicals S.A. | Novel compositions and methods |
| GB0906215D0 (en) | 2009-04-09 | 2009-05-20 | Lalvani Ajit | Diagnostic test |
| PL2528621T3 (pl) | 2010-01-27 | 2017-07-31 | Glaxosmithkline Biologicals S.A. | Zmodyfikowane antygeny gruźlicy |
| PL2661253T3 (pl) | 2011-01-04 | 2017-08-31 | Archivel Farma, Sl | Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy |
| ES2670493T3 (es) | 2012-01-12 | 2018-05-30 | Archivel Farma, S.L. | Vacuna de MTB-C contra respuestas alérgicas |
| CN104736555B (zh) * | 2012-10-23 | 2019-06-21 | 国家血清研究所 | 结核分枝杆菌疫苗 |
| AU2014232335C1 (en) | 2013-03-15 | 2016-09-01 | The Trustees Of The University Of Pennsylvania | Synthetic immunogens for prophylaxis or treatment of tuberculosis |
| US10641770B2 (en) * | 2013-12-16 | 2020-05-05 | Statens Serum Institut | Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis |
| RU2695462C2 (ru) * | 2014-01-09 | 2019-07-23 | Трансген Са | Гибридизация гетероолигомерных микобактериальных антигенов |
| JP2017513860A (ja) * | 2014-04-24 | 2017-06-01 | スタテンス セールム インスティトゥート | 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン |
| CN104151433A (zh) * | 2014-08-11 | 2014-11-19 | 兰州大学 | 一种结核分枝杆菌融合蛋白及其制备方法和应用 |
| CN104225591A (zh) * | 2014-09-15 | 2014-12-24 | 兰州大学 | 一种免疫佐剂及含有该免疫佐剂的疫苗 |
| US20200148729A1 (en) * | 2016-05-21 | 2020-05-14 | Infectious Disease Research Institute | Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections |
| MX2020011298A (es) | 2018-04-26 | 2021-01-29 | Childrens Nat Medical Ct | Composiciones de antígeno micobacteriano y métodos de uso. |
| CN110423279B (zh) * | 2019-06-20 | 2021-07-27 | 扩增生物科技(北京)有限公司 | 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用 |
| CN115598041B (zh) * | 2021-07-07 | 2025-08-19 | 中国科学院微生物研究所 | 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用 |
| KR102577332B1 (ko) * | 2021-12-29 | 2023-09-11 | 재단법인 오송첨단의료산업진흥재단 | 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물 |
| KR20250082868A (ko) | 2023-11-30 | 2025-06-09 | 서울대학교산학협력단 | 분비형 코리스메이트 뮤테이즈 (Rv1885c)가 약화된 Mycobacterium bovis BCG 균주, 이를 포함하는 백신용 조성물 및 이의 용도 |
| CN117777259B (zh) * | 2024-02-23 | 2024-06-07 | 上海科新生物技术股份有限公司 | 检测结核感染的抗原组合物、试剂盒及其应用 |
| CN120192426B (zh) * | 2025-03-04 | 2025-11-11 | 江西澄实生物科技有限公司 | 一种预防沙门氏菌感染的疫苗及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US6641814B1 (en) * | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
| US5955077A (en) * | 1993-07-02 | 1999-09-21 | Statens Seruminstitut | Tuberculosis vaccine |
| CN1105236A (zh) * | 1993-11-13 | 1995-07-19 | 丛繁滋 | 肺结核防传播及治疗用气雾剂及其制备方法 |
| CN1051234C (zh) * | 1994-04-15 | 2000-04-12 | 焦安国 | 一种治疗结核病的药物 |
| ATE339436T1 (de) | 1995-06-07 | 2006-10-15 | Sanofi Pasteur Inc | Expression von lipoproteinen |
| US6338852B1 (en) * | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6982085B2 (en) * | 1997-04-02 | 2006-01-03 | Statens Serum Institut | TB diagnostic based on antigens from M. tuberculosis |
| EP1200466A2 (en) | 1999-07-13 | 2002-05-02 | Statens Serum Institut | Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosisesat-6 gene family |
| WO2001079274A2 (en) | 2000-04-19 | 2001-10-25 | Statens Serum Institut | Tuberculosis antigens and methods of use thereof |
| GB0030368D0 (en) | 2000-12-13 | 2001-01-24 | Inst Of Molecul & Cell Biology | Dormancy-induced mycobacterium proteins |
| CA2433236C (en) * | 2001-01-08 | 2016-10-04 | Isis Innovation Limited | Assay to determine efficacy of treatment for m. tuberculosis infection |
| DE60236573D1 (de) * | 2002-04-05 | 2010-07-15 | Pasteur Institut | Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht |
| EP1523331B1 (en) * | 2002-07-13 | 2013-02-27 | Statens Serum Institut | Therapeutic tb vaccine |
| WO2004067718A2 (en) | 2003-01-24 | 2004-08-12 | Emory University | Necrosis-deficient mutants of tuberculosis bacteria |
| EP2226332A1 (en) * | 2004-06-17 | 2010-09-08 | Beckman Coulter, Inc. | Mycobacterium tuberculosis epitopes and methods of use thereof |
| NZ555907A (en) * | 2004-11-16 | 2009-12-24 | Aeras Global Tb Vaccine Found | Multivalent vaccines comprising recombinant viral vectors |
| MX2007008182A (es) * | 2005-01-05 | 2008-02-19 | Isis Innovation | Composiciones para inmunizar contra micobacteria. |
| PL2457926T3 (pl) | 2005-04-29 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
| AU2006261445B2 (en) | 2005-06-23 | 2011-03-31 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| RU2490024C2 (ru) * | 2006-06-28 | 2013-08-20 | Статенс Серум Инститьют | Расширение спектра т клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли |
| UA107330C2 (uk) | 2008-07-25 | 2014-12-25 | Глаксосмітклайн Байолоджікалз С.А. | Туберкульозний білок rv3616c та його застосування |
-
2010
- 2010-04-23 CN CN201080017717.7A patent/CN102413837B/zh active Active
- 2010-04-23 MX MX2011011186A patent/MX2011011186A/es active IP Right Grant
- 2010-04-23 TR TR2019/03223T patent/TR201903223T4/tr unknown
- 2010-04-23 US US13/262,914 patent/US9074001B2/en active Active
- 2010-04-23 AU AU2010238943A patent/AU2010238943B9/en not_active Ceased
- 2010-04-23 PL PL10766664T patent/PL2421557T3/pl unknown
- 2010-04-23 ES ES10766664T patent/ES2714383T3/es active Active
- 2010-04-23 CN CN201410141208.5A patent/CN104107425B/zh active Active
- 2010-04-23 WO PCT/DK2010/000054 patent/WO2010121618A1/en not_active Ceased
- 2010-04-23 BR BRPI1006452A patent/BRPI1006452A2/pt not_active Application Discontinuation
- 2010-04-23 DK DK10766664.6T patent/DK2421557T3/en active
- 2010-04-23 KR KR1020117028104A patent/KR20120014176A/ko not_active Ceased
- 2010-04-23 JP JP2012506340A patent/JP5839361B2/ja not_active Expired - Fee Related
- 2010-04-23 MX MX2015009347A patent/MX370744B/es unknown
- 2010-04-23 EP EP10766664.6A patent/EP2421557B1/en active Active
- 2010-04-23 KR KR1020177016378A patent/KR20170072366A/ko not_active Ceased
- 2010-04-23 CA CA2759583A patent/CA2759583C/en active Active
-
2011
- 2011-10-06 IL IL215591A patent/IL215591A/en active IP Right Grant
- 2011-11-22 ZA ZA2011/08564A patent/ZA201108564B/en unknown
-
2012
- 2012-07-11 HK HK15103708.0A patent/HK1204549A1/xx unknown
-
2014
- 2014-12-12 US US14/569,341 patent/US10519202B2/en active Active
-
2015
- 2015-06-24 JP JP2015127000A patent/JP6215260B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201903223T4 (tr) | Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. | |
| PH12014502250B1 (en) | Mycoplasma hyopneumoniae vaccine | |
| TR201802380T4 (tr) | Benzonaftiridin içeren aşılar. | |
| MX340830B (es) | Vacuna neumococica y usos de la misma. | |
| MX355366B (es) | Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. | |
| BR112013009164A2 (pt) | capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada. | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| EA201500054A1 (ru) | Аттенуированные вакцины против streptococcus suis и способы их получения и применения | |
| WO2016176624A3 (en) | Porcine pestvirus, vaccines, and assays | |
| EA201290956A1 (ru) | Вакцина против вич | |
| MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
| AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
| CO6670521A2 (es) | Vacuna y m´todos para reducir una infección por campylobacter | |
| EP2591090A4 (en) | BACTERIAL VACCINES ASSOCIATED WITH CERAMIDE GLYCOLIPIDS AND USES THEREOF | |
| MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
| WO2011112906A3 (en) | Novel immunogens and methods for discovery and screening thereof | |
| MX347911B (es) | Vacuna contra virus de diarrea viral de bovinos. | |
| WO2011082422A3 (en) | Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications | |
| WO2013173256A3 (en) | New and improved influenza vaccines | |
| MX2018012270A (es) | Novedosas formulaciones de vacuna neumococica. | |
| GB2515222A (en) | Use of flagellin as a vaccine | |
| WO2019143712A3 (en) | Induced common antibody response | |
| MX368601B (es) | Composicion inmunogenica contra la aeromonas hydrophila. | |
| TR201911128T4 (tr) | Neısserıa menıngıtıdıs fhbp varyantı ve bunun aşılamaya yönelik kullanımı. | |
| WO2010080188A3 (en) | Epitope targeted anthrax vaccine |